Melatonin Receptor Expression in Primary Uveal Melanoma

IF 4.9 2区生物学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

International Journal of Molecular Sciences Pub Date : 2024-08-09 DOI:10.3390/ijms25168711

Anna Hagström, Ruba Kal Omar, Hans Witzenhausen, E. Lardner, Oran Abdiu, Gustav Stålhammar

{"title":"Melatonin Receptor Expression in Primary Uveal Melanoma","authors":"Anna Hagström, Ruba Kal Omar, Hans Witzenhausen, E. Lardner, Oran Abdiu, Gustav Stålhammar","doi":"10.3390/ijms25168711","DOIUrl":null,"url":null,"abstract":"Melatonin, noted for its anti-cancer properties in various malignancies, including cutaneous melanoma, shows promise in Uveal melanoma (UM) treatment. This study aimed to evaluate melatonin receptor expression in primary UM and its association with UM-related mortality and prognostic factors. Immunohistochemical analysis of 47 primary UM tissues showed low expression of melatonin receptor 1A (MTNR1A) and melatonin receptor 1B (MTNR1B), with MTNR1A significantly higher in patients who succumbed to UM. Analysis of TCGA data from 80 UM patients revealed RNA expression for MTNR1A, retinoic acid-related orphan receptor alpha (RORα), and N-ribosyldihydronicotinamide:quinone oxidoreductase (NQO2), but not MTNR1B or G protein-coupled receptor 50 (GPR50). Higher MTNR1A RNA levels were observed in patients with a BRCA1 Associated Protein 1 (BAP1) mutation, and higher NQO2 RNA levels were noted in patients with the epithelioid tumor cell type. However, Kaplan–Meier analysis did not show distinct survival probabilities based on receptor expression. This study concludes that UM clinical samples express melatonin receptors, suggesting a potential mechanism for melatonin’s anti-cancer effects. Despite finding higher MTNR1A expression in patients who died of UM, no survival differences were observed.","PeriodicalId":49179,"journal":{"name":"International Journal of Molecular Sciences","volume":null,"pages":null},"PeriodicalIF":4.9000,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Molecular Sciences","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3390/ijms25168711","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Melatonin, noted for its anti-cancer properties in various malignancies, including cutaneous melanoma, shows promise in Uveal melanoma (UM) treatment. This study aimed to evaluate melatonin receptor expression in primary UM and its association with UM-related mortality and prognostic factors. Immunohistochemical analysis of 47 primary UM tissues showed low expression of melatonin receptor 1A (MTNR1A) and melatonin receptor 1B (MTNR1B), with MTNR1A significantly higher in patients who succumbed to UM. Analysis of TCGA data from 80 UM patients revealed RNA expression for MTNR1A, retinoic acid-related orphan receptor alpha (RORα), and N-ribosyldihydronicotinamide:quinone oxidoreductase (NQO2), but not MTNR1B or G protein-coupled receptor 50 (GPR50). Higher MTNR1A RNA levels were observed in patients with a BRCA1 Associated Protein 1 (BAP1) mutation, and higher NQO2 RNA levels were noted in patients with the epithelioid tumor cell type. However, Kaplan–Meier analysis did not show distinct survival probabilities based on receptor expression. This study concludes that UM clinical samples express melatonin receptors, suggesting a potential mechanism for melatonin’s anti-cancer effects. Despite finding higher MTNR1A expression in patients who died of UM, no survival differences were observed.

查看原文本刊更多论文

原发性葡萄膜黑色素瘤中褪黑激素受体的表达

褪黑素因其在包括皮肤黑色素瘤在内的多种恶性肿瘤中的抗癌特性而备受关注，它在葡萄膜黑色素瘤（UM）的治疗中也大有可为。本研究旨在评估原发性葡萄膜黑色素瘤中褪黑激素受体的表达及其与葡萄膜黑色素瘤相关死亡率和预后因素的关系。对47例原发性UM组织的免疫组化分析显示，褪黑激素受体1A（MTNR1A）和褪黑激素受体1B（MTNR1B）的表达量较低，而在UM死亡患者中，MTNR1A的表达量明显较高。对80名UM患者的TCGA数据进行分析后发现，MTNR1A、视黄酸相关孤儿受体α（RORα）和N-核osyldihydronicotinamide:醌氧化还原酶（NQO2）都有RNA表达，但MTNR1B或G蛋白偶联受体50（GPR50）却没有。在BRCA1相关蛋白1（BAP1）突变的患者中观察到较高的MTNR1A RNA水平，在上皮样肿瘤细胞类型的患者中观察到较高的NQO2 RNA水平。然而，Kaplan-Meier分析并未显示受体表达不同的生存概率。本研究得出结论：UM 临床样本表达褪黑激素受体，表明褪黑激素抗癌作用的潜在机制。尽管发现死于荨麻疹的患者中MTNR1A表达较高，但未观察到生存率差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Molecular Sciences Chemistry-Organic Chemistry

CiteScore

8.10

自引率

10.70%

发文量

13472

审稿时长

17.49 days

期刊介绍： The International Journal of Molecular Sciences (ISSN 1422-0067) provides an advanced forum for chemistry, molecular physics (chemical physics and physical chemistry) and molecular biology. It publishes research articles, reviews, communications and short notes. Our aim is to encourage scientists to publish their theoretical and experimental results in as much detail as possible. Therefore, there is no restriction on the length of the papers or the number of electronics supplementary files. For articles with computational results, the full experimental details must be provided so that the results can be reproduced. Electronic files regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material (including animated pictures, videos, interactive Excel sheets, software executables and others).